Julphar announces the sale of its subsidiary Diabtech LLC to streamline operations and focus on core diabetes solutions, paving the way for new product development and strategic growth in the pharmaceutical sector.

Information on the Target

Julphar, officially known as Gulf Pharmaceutical Industries, is one of the largest pharmaceutical manufacturers in the Middle East and Africa. Established in 1980 under the guidance of His Highness Sheikh Saqr bin Mohammed Al Qasimi, the company has gained a reputation for providing innovative and cost-effective healthcare solutions to families globally. Julphar employs over 3,500 personnel and distributes pharmaceutical products across approximately 40 countries. Its core operations are divided into two main segments: Julphar Diabetes Solutions and the General Medicine Division. The commitment to high-quality manufacturing is reflected in its 12 internationally accredited facilities located in Ras Al Khaimah, UAE.

Industry Overview in the Target’s Specific Country

The pharmaceutical industry in the United Arab Emirates (UAE) is rapidly evolving, driven by increasing demand for healthcare services and products. The UAE has positioned itself as a regional hub for pharmaceutical manufacturing, with a focus on growing the local industry through incentives and support from the government. A rise in chronic diseases, such as diabetes and cardiovascular disorders, is propelling the need for advanced pharmaceutical solutions, thus creating a vast market opportunity for firms operating in this space.

Furthermore, the UAE government has been proactive in establishing regulatory frameworks that encourage innovation and growth within the pharmaceutical sector. This in